1 / 21

Enrico Bertini, MD Bambino Gesu’Children’s Research Hospital Rome, Italy

Barcelona, May 21 2005 V Jornada Medico Informativa Atrofia Muscular Espinal (AME). Mesa redonda: Futuro de la investigacion y tratamiento de AME. Enrico Bertini, MD Bambino Gesu’Children’s Research Hospital Rome, Italy. Four types of SMA but functionally 3 types of SMA

lambjohn
Télécharger la présentation

Enrico Bertini, MD Bambino Gesu’Children’s Research Hospital Rome, Italy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Barcelona, May 21 2005 V Jornada Medico Informativa Atrofia Muscular Espinal (AME) Mesa redonda: Futuro de la investigacion y tratamiento de AME Enrico Bertini, MD Bambino Gesu’Children’s Research Hospital Rome, Italy

  2. Four types of SMA but functionally 3 types of SMA • representing 3 different disability phenotypes • Age at onset • Maximum function achieved • different severity • progression • disability • different • natural history • standard care • outcome measures (trials)

  3. SMA • TYPE I • age of onset < 6 months • children never acquire the ability to sit unsupported • die of respiratory problems by the age of 2 years • TYPE II • age of onset between 6 and 18 months • children are able to sit unsupported but not to walk • TYPE III • age of onset > 18 months • patients are able to walk independently

  4. Crawford & Pardo Neurobiol Dis, 1996;3:97–110 Russman, et al., Neurology. 1996 Oct;47(4):973-6.Zerres et al., J Neurol Sci 146(1 997) 67-7 Still sitting Age at death

  5. Clinical Trials • Type of SMA(different disability phenotypes) • Natural history (information for inclusion criteria) • Outcome measures (primary and secondary) • Standard of Care (best management of patients, and control of confounding factors)

  6. Four classes of factors influence strength and function 1)Amount of SMN reduction 2)Other genetic factors 3)Growth, age, motor unit remodelling 4)Systemic consequences of muscle weakness (immobility, reduced muscle mass, gastrointestinal illness, respiratory cachexia, obesity) Crawford TO Neurmusc Disord 2004 14: 456-460

  7. SMA type I -Standard care • Pulmonary management • Manual or Mechanical Percussion, • Postural Drainage, • Intrapulmonary Percussive Ventilation, • The Vest Airway Clearance System, assisted coughs and • In-exsufflator cough machine or Cough Assist device • Periodic BiPAP, and use of nasal nocturnal ventilation. • The natural history and life expectancy changes in SMA type I • whether you use non-invasive ventilation or not.

  8. SMA type I/SMA type II/SMA type III -Standard care • Nutrition, feeding supplementation option • Gastrointestinal, gastrostomy • Growth measures • Dexa (lean body and fat mass) • Skinfold thickness • Weight, length, head, chest and arm circumference • Lab screening of blood count, metabolic screen and • nutritional markers • Positioning and posturing management • Physiotherapy • KAFOS (when applicable) • ORLAU Parawalker

  9. SMA type II /SMA type III -Standard care • Periodic controls • Every 6 months (?) for monitoring scoliosis (once scolisis appears, • control every 3 months) • Respiratory care in SMA type II (Manzur et al., Neuromuscul Disord (2003) 3: 184–9; • Wallgren-Pettersson et al., Neuromuscular Disorders 14 (2004) 56–69) • Every year for FVC ifFVC <40% predicted. • Poor cough, low VC PCF • SDB and NH overnight pulse oximetry recording • Ventilatory support

  10. SMA type I- Outcome measures • A. Life expectancy • B. Functional motor testing • CHOP test of strength in SMA, a newly created test of elicited motor responses (Finkel et al., 2004) • Test of infant motor performance (TIMP) (Finkel et al., 2004) • C. Electrophysiological studies: MUNE versus CMAP • (Bromberg & Swoboda, 2002) • D. Respiratory muscle function • Tension time index (TTI) and its derivative (ttmus): measures of respiratory pump muscle fatigue • Maximal inspiratory pressure (MIP): measure of a brief burst of inspiratory strength.  • Phase angle (F), the labored breathing index (LBI), and phase relation during the total breath (phrtb): measures of thoracoabdominal synchrony, or the efficiency of respiratory system mechanics and the rapid shallow breathing index (RSBI) as a measure of the respiratory pattern.

  11. SMA type II/SMA Type III -Outcome measures • Primary functional outcome measures (children after age 2,5 years) • Timed tests: 1) walking 10 meters; 2) climbing/descending stairs; 3) rising from the floor. • The Hammersmith functional motor scale • The Gross Motor Function Measure (GMFM) ? • Mesure de Fonction Motrice (M F M) • Primary strength outcome measures (children older than 5 years) • Quantitative muscle testing • The Richmond Quantitative Measurement System • Hand-held CITEC Myometer • Secondary outcome measures • Pulmonary function tests (FVC) • Maximum inspiratory pressure (cm of water), Maximum expiratory pressure (cm of water), Cough pressure (peak cough flow, liter per minute), First respiratory volume in the first second (litres)

  12. SMA type I/SMA type II/SMA type III- QOL Quality of life (QL) PedsQL Neuromuscular Module for Parents (Iannaccone ST et al., 2003) Caregiver burden questionaires

  13. We need to reconstruct a natural history using outcome measures The experience with the Hammersmith functional motor score Main et Eur J Paediatr Neurol (2003) 7:155-59.

  14. SCORE 2 POINTS1 POINTSCORE 0 Chair sitting,no hand support 1 hand 2 hand support Long sitting, no hands 1 hand 2 hand support Hands to head,able flexes head unable Two hands to head,able flexes head unable ½ roll from supine, both ways one way unable Rolls prone to supine(R) push on hand unable Rolls prone to supine(S) push on hand unable Rolls supine to prone(R) push on hand unable Rolls supine to prone(S) push on hand unable Lifts head from prone unable Lifts head from supine through side flexion unable Sitting from lying unalbe Lying form sitting unable Prop on forearms-head up hold position when placed unable Prop on extendend arms-head up hold position when placed unable 4 point kneeling-head up hold position when placed unable Crawls unable Stands holding-one hand minimal trunk support orthosis needed Stands independently> 3’’ <3’’ stands momentarily Takes > 4 steps, unaided 2-4 steps unable

  15. METHODS Inclusion criteria: Children with genetic diagnosis of SMA SMA II or non-ambulant SMA III Age: from 2 ½ to 12 years. Exclusion criteria : Previous spinal fusion surgery Pharmacological treatments (Salbutamol, creatine, gabapentin) within 60 days Other major medical conditions HFMS scale was assessed at baseline (T0) and after 3 months (T1) and others after 6 months by two examiners, which had training session with a senior physiotherapist

  16. Multicenter trial (10 centers in Italy) Enrolled 88 patients with SMAII or SMAIII who lost walking ceiling effects floor Count of variation T0/T1 64 Average of variation T0/T1 -0.27 SD of variation T0/T1 1.01

  17. Multicenter trial (10 centers in Italy) Enrolled 88 patients with SMAII or SMAIII who lost walking Count of variation T0/T1 24 Average of variation T0/T1 -0.13 SD of variation T0/T1 1.60

  18. Future developments for international Consensus • ENMC Standard of Care Forum • ENMC SMA functional scales Forum • International Coordination Committee on SMA (ICC) • Standard Care sub-committee • Outcome measures sub-committee • SMA Clinical Trial Design sub-committee • Patient Registry sub-committee

  19. ENMC Workshop Feb 2005 Enrico Bertini (Rome, Italy) Arthur Burghes A (Colombus, USA) Kate Bushby K( Newcastle upon Tyne, UK), Richard Finkel R (USA) Natahlie Goemans (Leuven, Belgium) Susan Iannaccone S ( USA) Maria Jdrzejowska (Varsaw, Poland) Jeannet Pierre Yves (Lausanne, Switzerland) Marion Main (London, UK) Anita Macaulay (Starford upon Avon , UK) Domenico Marchetti (Rome, Italy) Judith Melki ( Evry, France) Eugenio Mercuri (Rome, Italy) Francesco Muntoni (London, UK) Thomas Voit (Essen, Germany) Anita Simmonds (London, UK) Alessandra Solari (Milano, Italy) Volker Straub (Newcastle upon Tyne, UK) Kathryn Swoboda (USA) Danilo Tiziano (Rome, Italy) Edoardo Tizzano, Barcelona, Spain) Haluk Topaloglu H (Ankara, Turkey) Louis Viollet (Paris, France) Dick Willems, (Amsterdam, The Netherlands) Brunhilde Wirth (Cologne, Germany) Klaus Zerres K (Aachen, Germany) Richard Hughes (London) Christina Brahe (Rome) Brigitte Estournet-Mathiaud (Paris) Andoni J.Urtizberea (Paris, France) Luciano Merlini (Bologna, Italy) Victor Dubowitz (London, UK) ICC on SMA Karen Rabb (USA) Shree Pandya (USA) Leslie Nelson (USA) Jill Jarecki (USA) Cynthia Joyce (USA) Sandy Pacholick (USA) Linda S. Hynan (USA) Brenda Wong (USA) Thomas Crawford (USA) Jiri Vajsar (Canada) Anne Connolly (USA) Mary Schroth (USA) Ching Wang (USA) Leslie Morrison (USA) Uwe Mellies (Germany) Kaufmann, Petra (USA) Linda Hynan (USA) John Kissel (USA) Michael McDermott (USA) Tan Nguyen (USA)

More Related